Free Trial

GSK (GSK) Stock Price, News & Analysis

GSK logo
$38.52 -0.43 (-1.10%)
Closing price 03:59 PM Eastern
Extended Trading
$38.56 +0.04 (+0.12%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About GSK Stock (NYSE:GSK)

Key Stats

Today's Range
$38.28
$38.87
50-Day Range
$36.25
$42.50
52-Week Range
$31.72
$44.67
Volume
4.88 million shs
Average Volume
4.93 million shs
Market Capitalization
$78.86 billion
P/E Ratio
19.86
Dividend Yield
4.39%
Price Target
$37.38
Consensus Rating
Hold

Company Overview

GSK Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
41st Percentile Overall Score

GSK MarketRank™: 

GSK scored higher than 41% of companies evaluated by MarketBeat, and ranked 698th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    GSK has received a consensus rating of Hold. The company's average rating score is 2.10, and is based on no buy ratings, 8 hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    GSK has only been the subject of 3 research reports in the past 90 days.

  • Read more about GSK's stock forecast and price target.
  • Earnings Growth

    Earnings for GSK are expected to grow by 12.32% in the coming year, from $4.14 to $4.65 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of GSK is 19.86, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.21.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of GSK is 19.86, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 26.21.

  • Price to Earnings Growth Ratio

    GSK has a PEG Ratio of 1.34. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    GSK has a P/B Ratio of 4.77. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about GSK's valuation and earnings.
  • Percentage of Shares Shorted

    0.82% of the float of GSK has been sold short.
  • Short Interest Ratio / Days to Cover

    GSK has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in GSK has recently decreased by 1.14%, indicating that investor sentiment is improving.
  • Dividend Leadership

    GSK is a leading dividend payer. It pays a dividend yield of 4.39%, putting its dividend yield in the top 25% of dividend-paying stocks.

  • Dividend Growth

    GSK does not have a long track record of dividend growth.

  • Dividend Coverage

    The dividend payout ratio of GSK is 87.11%. Payout ratios above 75% are not desirable because they may not be sustainable.

  • Dividend Sustainability

    Based on earnings estimates, GSK will have a dividend payout ratio of 36.34% next year. This indicates that GSK will be able to sustain or increase its dividend.

  • Read more about GSK's dividend.
  • Percentage of Shares Shorted

    0.82% of the float of GSK has been sold short.
  • Short Interest Ratio / Days to Cover

    GSK has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in GSK has recently decreased by 1.14%, indicating that investor sentiment is improving.
  • News Sentiment

    GSK has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.90 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 19 news articles for GSK this week, compared to 19 articles on an average week.
  • Search Interest

    37 people have searched for GSK on MarketBeat in the last 30 days. This is an increase of 185% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added GSK to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, GSK insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 10.00% of the stock of GSK is held by insiders.

  • Percentage Held by Institutions

    Only 15.74% of the stock of GSK is held by institutions.

  • Read more about GSK's insider trading history.
Receive GSK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter.

GSK Stock News Headlines

GSK’s New IPF Drug Study: Potential Market Impact
Trump’s Exec Order #14154 could be a “Millionaire-Maker”
Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans a chance at true financial independence in the months ahead.” We recently sat down with Rickards to capture all the key details on tape.
See More Headlines

GSK Stock Analysis - Frequently Asked Questions

GSK's stock was trading at $33.82 at the beginning of the year. Since then, GSK stock has increased by 13.9% and is now trading at $38.52.
View the best growth stocks for 2025 here
.

GSK PLC Sponsored ADR (NYSE:GSK) posted its quarterly earnings data on Wednesday, April, 30th. The pharmaceutical company reported $1.13 earnings per share for the quarter, beating analysts' consensus estimates of $1.08 by $0.05. The firm's revenue for the quarter was up 2.1% on a year-over-year basis.
Read the conference call transcript
.

Shares of GSK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that GSK investors own include Chevron (CVX), BlackRock (BLK), Broadcom (AVGO), UnitedHealth Group (UNH), Bristol Myers Squibb (BMY), Meta Platforms (META) and NVIDIA (NVDA).

Company Calendar

Record date for 4/10 Dividend
2/21/2025
Ex-Dividend for 4/10 Dividend
2/21/2025
Dividend Payable
4/10/2025
Last Earnings
4/30/2025
Record date for 7/10 Dividend
5/16/2025
Ex-Dividend for 7/10 Dividend
5/16/2025
Today
7/02/2025
Dividend Payable
7/10/2025
Next Earnings (Estimated)
7/30/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NYSE:GSK
Employees
68,629
Year Founded
2000

Price Target and Rating

Average Stock Price Target
$37.38
High Stock Price Target
$39.50
Low Stock Price Target
$35.25
Potential Upside/Downside
-3.0%
Consensus Rating
Hold
Rating Score (0-4)
2.10
Research Coverage
10 Analysts

Profitability

Trailing P/E Ratio
19.86
Forward P/E Ratio
9.30
P/E Growth
1.34
Net Income
$3.29 billion
Pretax Margin
13.37%

Debt

Sales & Book Value

Annual Sales
$40.10 billion
Cash Flow
$5.60 per share
Price / Cash Flow
6.88
Book Value
$8.07 per share
Price / Book
4.77

Miscellaneous

Outstanding Shares
2,047,350,000
Free Float
1,842,612,000
Market Cap
$78.86 billion
Optionable
Optionable
Beta
0.50

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NYSE:GSK) was last updated on 7/2/2025 by MarketBeat.com Staff
From Our Partners